



What is minimal residual disease (MRD)?



se (MRD)?&source=https://www.myeloma.org)  (https://www.myeloma.org/node/8429/printable/print)

Minimal Residual Disease (MRD) and MRD Testing Methods

Myeloma expert Dr. Brian G.M. Durie answers the question: what is MRD or minimal residual disease? And explains how MRD testing can help speed up the approval of new myeloma drugs.

[Privacy settings](#)

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services.

WITHDRAW CONSENT

ASK A QUESTION

Please note that Ask Dr. Durie has been discontinued, and it was designed to address myeloma questions of the broadest possible audience interest. If you have a question of a personal nature, **please contact our InfoLine Coordinators at 800.452.2873 or info@myeloma.org** (mailto:info@myeloma.org) **(Please do not send email attachments or lab reports.)**.

VIDEO TRANSCRIPT

[Click to view the transcript](#)



This week's "Ask Dr. Durie" comes from a gentleman who wants to know what MRD is. MRD stands for minimal residual disease, which is a level of disease achieved as part of deep responses. The level of MRD is very low and is measured on bone marrow samples using new technology, either genetic testing called next-generation sequencing, or flow technology where the bone marrow sample is passed through a flow machine to detect any passing myeloma cells. This is called next-generation flow. With this technology, there is a high level of sensitivity in detecting one out of 100,000 cells, or even one out of a million cells, or even more. This ten to the minus five or ten to the minus six sensitivity, as it is called, is extremely helpful in documenting that deep response has been achieved.

The value of this methodology is that one can tell if modern therapies are producing better results. If therapy produces a ten to the minus six MRD level, this could be better than other older therapies where this is not achieved. So, the BOTTOM LINE is that MRD is an important new technology primarily used within trials to document if one therapy is better than another.

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services.



Dr. Brian G.M. Durie (1942-2025) was the co-founder of the IMF. He was a Professor of Medicine, Hematologist/Oncologist, and Honoree MD at the University of Brussels.




ASCO 2014: Survival benefit and cost of Auto HSCT in elderly patients with MM (/videos/asco-2014-survival-benefit-cost-auto-hsct-elderly-patients-mm)

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services.

Εδραίωση με **Carfilzomib, Lenalidomide** και **Dexamethasone (KRd)** Μετά από **ASCT**
Αποτελέσματα σε υψηλές τιμές ελάχιστης υπολειμματικής παθολογικής νόσου και βελτιώνει τον μεταβολισμό των οστών, στην απουσία διφωσφονικών, μεταξύ πρόσφατα διαγνωσμένων ασθενών με **πολλαπλό μυέλωμα**



Maria Gavriatopoulou, MD
National and Kapodistrian University of Athens
School of Medicine
Athens, Greece



Εδραίωση με Carfilzomib, Lenalidomide και Dexamethasone (KRd) (/videos/edraiosi-me-carfilzomib-lenalidomide-kai-dexamethasone-krd)

ASH 2019

READ MORE (/VIDEOS/EDRAIOSI-ME-CARFILZOMIB-LENALIDOMIDE-

PREVIOUS POST (/VIDEOS/DEXAMETHASONE-STILL-USED-PART-MYELOMA-THERAPY)

KRD)

NEXT POST (/VIDEOS/MGUS)



GIVE WHERE MOST NEEDED

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services.

